Semaglutide, a newly available glucagon-like peptide receptor agonist, shows remarkable favorable effects in hemodialysis patients with obesity and Type 2 diabetes

Ther Apher Dial. 2022 Feb;26(1):242-243. doi: 10.1111/1744-9987.13651. Epub 2021 Apr 19.

Authors

Suguru Saito¹, Toshiyuki Nakao²

Affiliations

¹ Department of Nephrology, Tokyo Medical University, Tokyo, Japan.
² Organization for Kidney Metabolic Disease Treatment, Tokyo, Japan.

PMID: 33830659
DOI: 10.1111/1744-9987.13651

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Diabetes Mellitus, Type 2 / complications*
Diabetes Mellitus, Type 2 / drug therapy*
Female
Glucagon-Like Peptide Receptors / agonists*
Glucagon-Like Peptides / therapeutic use*
Humans
Japan
Kidney Failure, Chronic / complications*
Kidney Failure, Chronic / therapy
Male
Middle Aged
Obesity / complications*
Renal Dialysis*
Treatment Outcome

Substances

Glucagon-Like Peptide Receptors
semaglutide
Glucagon-Like Peptides